A Phase 2 interventional study of APSTZD 1 and APSTZD 2 in Insomnia and Insomnia Chronic, sponsored by Apsen Farmaceutica S.A.. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Apsen Farmaceutica S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Sleep Initiation and Maintenance Disorders with a site in Brazil — 16 open to participants now, 17 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · Brazil.
Among the 45 studies in Sleep Initiation and Maintenance Disorders with a site in Brazil, this one is the 14th largest by planned enrollment of the 41 interventional ones that give a count, is one of 7 that started in 2026, is the only one in phase 2, reaches primary completion later than 11 of the 16 other live ones, and was the 42nd registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →16 of the 45 studies in Sleep Initiation and Maintenance Disorders with a site in Brazil are open now. Recruiting first, the newest first:
Telethon Kids Institute · Sites in Brazil, Australia
Ages 2–15
Federal University of Jatai · Sites in Brazil
Ages 30–59
Federal University of Pelotas · Sites in Brazil
Ages 60–75 · Women only · Healthy volunteers
University of Sao Paulo · Sites in Brazil
Ages 30–75
University of Sao Paulo · Sites in Brazil
Ages 18–65
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 10 · Phase 4 6
First in 2007; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 222 is above the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 75 across the 41 interventional studies, 187 across the 4 observational. Of the 22 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 45 have an industry lead sponsor. The 10 most frequent:
Apsen Farmaceutica S.A. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Apsen Farmaceutica S.A. has 1 study filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
4 of the studies in Sleep Initiation and Maintenance Disorders with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06636006Universidade Federal de GoiasAerobic Exercise Versus Digital Cognitive Behavioral Therapy for Insomnia | 2026-12-30 |
| NCT06692842University of Sao Paulo General HospitalInteractive Technological Intervention to Improve Mental Health Symptoms in Primary Health Care | 2026-12-31 |
| NCT07156708Federal University of PelotasAquatic Exercises Combined With Cognitive Tasks for Older Adults | 2027-08 |
| NCT06817109University of Sao Paulo General HospitalImplementation of Internet-based Psychotherapy for Symptoms of Depression, Insomnia and Anxiety in Primary Care in the Cities of Indaiatuba and Jaguariuna | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Sleep Initiation and Maintenance Disorders with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of APSTZD compared to one active drug and placebo in insomnia treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 oral tablets, once a day, before bedtime, for 6 weeks.
Drug: APSTZD 1
5 oral tablets, once a day, before bedtime, for 6 weeks.
Drug: APSTZD 2
5 oral tablets, once a day, before bedtime, for 6 weeks.
Drug: APSTZD 3
5 oral tablets, once a day, before bedtime, for 6 weeks.
Drug: APSTZD 4
5 oral tablets, once a day, before bedtime, for 6 weeks.
Drug: Stilnox CR®
5 oral tablets, once a day, before bedtime, for 6 weeks.
Drug: Placebo
APSTZD + placebo test 2 + placebo test 3 + placebo test 4 + comparator placebo 1
APSTZD + placebo test 1 + placebo test 3 + placebo test 4 + comparator placebo 1
APSTZD + placebo test 1 + placebo test 2 + placebo test 4 + comparator placebo 1
APSTZD + placebo test 1 + placebo test 2 + placebo test 3 + comparator placebo 1
Stilnox CR® + placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4
placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4 + comparator 1
Reduction in WASO 6h (Wake After Sleep Onset) assessed by polysomnography
Time frame: Change from baseline after 2 weeks of treatment
Adverse events incidence and classification
Time frame: Through study completion, up to 6 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.
Of 27 industry-sponsored phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's planned 16 months is above that.
Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →
Apsen Farmaceutica S.A.